X4 Pharmaceuticals (XFOR) Intangibles (2019 - 2026)

X4 Pharmaceuticals (XFOR) has reported Intangibles for 4 consecutive years, with $13.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Intangibles rose 36.11% year-over-year to $13.1 million; the trailing twelve-month figure through Jun 2026 stood at $13.1 million (up 36.11% YoY), and the FY2025 full-year result was $9.3 million, down 7.0% from the prior year.
• Intangibles grew to $13.1 million in Q2 2026 per XFOR's latest filing, from $9.1 million in the prior quarter.
• Across five years, Intangibles topped out at $13.1 million in Q2 2026 and bottomed at $9.1 million in Q1 2026.
• Historically, Intangibles has averaged $10.1 million across 3 years, with a median of $9.8 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Intangibles decreased 7.47% in 2025, then surged 36.11% in 2026.
• Over 3 years, Intangibles stood at $10.0 million in 2024, then fell by 7.0% to $9.3 million in 2025, then surged by 40.87% to $13.1 million in 2026.
• According to Business Quant data, Intangibles over the past three periods registered $13.1 million, $9.1 million, and $9.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.